KROS

Keros Therapeutics ($KROS) Major Shareholder Snaps Up $9.2M in Shares After Stock Collapse, Company Adopts Poison Pill Amid Sale Speculation

04/12/2025 02:01

A major shareholder of Keros Therapeutics ($KROS) has made a significant purchase following the company's stock collapse, drawing market attention. On April 9, ADAR1 Capital Management acquired 934,258 shares (worth approximately $9.21 million) at an average price of $9.86 per share, just before the company announced a strategic review and adoption of a poison pill defense. Keros Therapeutics is a clinical-stage biopharmaceutical company developing therapeutics that regulate TGF-β protein signaling. The company's key pipeline candidates include KER-050 for myelodysplastic syndromes and myelofibrosis, KER-012 for pulmonary arterial hypertension, and KER-065 for neuromuscular diseases. $KROS has experienced extreme price volatility over the past four months. After reaching a high of $70 in early December last year, the stock plummeted when the company announced on January 15 that it was halting clinical trials for its pulmonary arterial hypertension treatment, cibotercept, due to safety concerns. Following this announcement, the share price crashed more than 83% in a single day, from $63.07 to $10.42, and has since fluctuated in the low $10 range. Against this backdrop, ADAR1 Capital Management's substantial purchase carries particular significance. According to insider trading reports, ADAR1 may be deemed to indirectly beneficially own these securities through its layered ownership structure. The day after the purchase, on April 10, Keros announced a "review of strategic alternatives" along with the adoption of a poison pill, sending the stock up 18.8% to $12.27. Keros's moves appear closely related to the timing of the major insider purchase. The poison pill adoption suggests the company is preparing against potential hostile takeover attempts, while the strategic review indicates consideration of various options, including a possible sale of the company. Notably, Keros maintains a strong financial position. According to the most recent financial reports, the company holds approximately $559.9 million in cash with a debt ratio of just 3.3%. This means the company holds more cash than its current market capitalization (approximately $500 million), suggesting significant intrinsic value despite the clinical trial setback. Investment bank analysts maintain a relatively positive outlook. Although stock performance has been poor (down 23.06% year-to-date and 80.32% year-over-year), analysts are focusing on the value of Keros's pipeline, projecting first-quarter revenue to increase by more than 68,000% year-over-year to $56.65 million. Experts interpret ADAR1 Capital's major purchase as a vote of confidence in Keros's undervalued position. "This move by a major shareholder could signal that the current share price doesn't adequately reflect the company's actual value, particularly its cash holdings and remaining pipeline value," said one biotech analyst. ADAR1 Capital's position will likely be a critical variable in Keros's strategic review process. If the company is considering a potential sale, ADAR1 has secured greater influence through this insider transaction. Investors should monitor whether additional insider transactions occur in the coming weeks and how the company's strategic review progresses. Additionally, the cibotercept clinical data scheduled for release in Q2 could significantly impact the company's future direction. Although the trial was halted, a complete data analysis might provide insights into other indications or development paths. This insider transaction exemplifies a 'value investment' pattern common in the biotech sector—insiders betting on a company with substantial cash reserves through low-price purchases following a major clinical failure. Whether this investment bears fruit depends on the success of Keros's remaining pipeline and its strategic decisions going forward.

You can receive notifications when news is published.